Dr. Young on Other Options for Managing Bleeding in Children With Cancer

Guy Young, MD
Published: Monday, Oct 23, 2017



Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 


Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x